8-K: Aspira Women's Health Reports Record OvaSuite Revenue for 2024 Despite Unchanged Total Product Revenue

Aspira Women's Health announces its fourth quarter and full year 2024 financial results, highlighting record OvaSuite revenue and test volume despite overall product revenue remaining flat year-over-year.

Summary

• Aspira Women's Health reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Product revenue for the fourth quarter increased by 9.5% to $2.3 million compared to $2.1 million in the same period of 2023.
• OvaSuite tests performed in Q4 2024 increased by 6.1% to approximately 6,004, compared to 5,659 in Q4 2023.
• The average unit price (AUP) for OvaSuite tests in Q4 2024 increased by 4.3% to $391, compared to $376 in Q4 2023.
• Gross profit margin improved by 6.2 percentage points to 63.4% for Q4 2024, compared to 57.2% in Q4 2023.
• Total operating expenses for Q4 2024 decreased by 8% to $4.9 million.
• The company's cash balance as of March 27, 2024, was approximately $3.7 million, excluding a pending $1.5 million ARPA-H milestone payment.
• Aspira raised $5.75 million through a convertible note raise and its At-The-Market (ATM) facility in Q4 2024 and subsequent to year end.
• For the full year 2024, product revenue remained unchanged at $9.2 million compared to 2023.
• OvaSuite tests performed for the full year increased by 1.3% to approximately 24,305.
• The average unit price (AUP) for the full year decreased by 1.0% to $378.
• Gross profit margin for the full year improved by 2.2 percentage points to 59.7%.
• Total operating expenses for the full year decreased by 10% to $21.8 million.
• The company received a $10 million Federal Government investment in ENDOinform.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company shows improvements in gross profit and operating expense reduction, revenue growth is stagnant for the full year. The successful capital raise and government investment are positive signs, but the accumulated deficit remains a concern.

Positives

• Product revenue increased in Q4 2024 by 9.5% to $2.3 million.
• OvaSuite test volume increased by 6.1% in Q4 2024.
• Gross profit margin improved to 63.4% in Q4 2024.
• Operating expenses decreased by 8% in Q4 2024.
• The company successfully raised $5.75 million through financing activities.
• Aspira secured a $10 million Federal Government investment in ENDOinform.
• The company appointed a new CEO and a new member to the Board of Directors.

Negatives

• Product revenue for the full year 2024 remained unchanged at $9.2 million.
• The average unit price (AUP) for the full year decreased by 1.0% to $378.
• The company had a net loss of $1.388 million for the quarter and $13.094 million for the year.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's cash balance as of March 27, 2024, was approximately $3.7 million, excluding a pending $1.5 million ARPA-H milestone payment, which may indicate a need for additional funding.
• The company's accumulated deficit is significant at $(531.397) million as of December 31, 2024.

Future Outlook

The company's strategic focus in 2025 and beyond is to rapidly accelerate top-line revenue growth through an improved go-to-market strategy, run a leaner cost model, and explore new in-licensing opportunities and strategic collaborations.

Management Comments

• The Aspira team generated record test volume and revenue in a challenging environment in 2024.
• We are deeply committed to meeting the medical needs of millions of women that benefit from the life-saving capabilities of our early detection OvaSuite product.
• Looking ahead, our strategic focus in 2025 and beyond is to rapidly accelerate top-line revenue growth through our improved go-to-market strategy.
• This funding will accelerate our near-term pipeline, fuel meaningful growth, and drive new strategic partnerships to make a lasting impact on womens health.

Industry Context

Aspira operates in the women's health diagnostics market, focusing on ovarian cancer and endometriosis. The company's focus on AI-enabled tests and non-invasive diagnostics aligns with the broader industry trend towards personalized medicine and early disease detection.

Comparison to Industry Standards

• Exact Sciences (EXAS) is a comparable company in the diagnostics space, focusing on early cancer detection.
• Myriad Genetics (MYGN) also offers diagnostic tests for women's health, including hereditary cancer risk assessment.
• Aspira's OvaSuite aims to provide a comprehensive portfolio of blood tests for ovarian cancer risk detection, similar to how companies like Veracyte (VCYT) offer genomic tests for various cancers.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased value through revenue growth and strategic initiatives.
• Employees: Focus on sales growth and leaner cost model may impact job roles and responsibilities.
• Customers: Continued access to diagnostic tools for gynecologic diseases.
• Patients: Potential for improved diagnostics and treatment pathways for ovarian cancer and endometriosis.

Next Steps

• Rapidly accelerate top-line revenue growth through an improved go-to-market strategy.
• Run a leaner cost model, dedicating more financial resources to sales growth.
• Explore new in-licensing opportunities, channel partners, and other strategic collaborations.
• Continue research and development to expand the ovarian cancer portfolio and address the need for non-invasive diagnostics for endometriosis.

Key Dates

Keywords

OvaSuite, Aspira Women's Health, Financial Results, Ovarian Cancer, Diagnostics, Revenue, Gross Profit, ENDOinform